HK1252369A1 - 利用納米顆粒治療腫瘤的組合物和方法 - Google Patents

利用納米顆粒治療腫瘤的組合物和方法

Info

Publication number
HK1252369A1
HK1252369A1 HK18111665.1A HK18111665A HK1252369A1 HK 1252369 A1 HK1252369 A1 HK 1252369A1 HK 18111665 A HK18111665 A HK 18111665A HK 1252369 A1 HK1252369 A1 HK 1252369A1
Authority
HK
Hong Kong
Prior art keywords
compositions
methods
tumor treatment
treatment utilizing
utilizing nanoparticles
Prior art date
Application number
HK18111665.1A
Other languages
English (en)
Inventor
莊其穆
張启泰
Original Assignee
友杏生技醫藥股份有限公司
建州生技醫藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 友杏生技醫藥股份有限公司, 建州生技醫藥有限公司 filed Critical 友杏生技醫藥股份有限公司
Publication of HK1252369A1 publication Critical patent/HK1252369A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18111665.1A 2015-02-13 2018-09-11 利用納米顆粒治療腫瘤的組合物和方法 HK1252369A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562115635P 2015-02-13 2015-02-13

Publications (1)

Publication Number Publication Date
HK1252369A1 true HK1252369A1 (zh) 2019-05-24

Family

ID=56614965

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18111665.1A HK1252369A1 (zh) 2015-02-13 2018-09-11 利用納米顆粒治療腫瘤的組合物和方法

Country Status (12)

Country Link
US (1) US10016365B2 (zh)
EP (1) EP3256110A4 (zh)
JP (1) JP2018505224A (zh)
KR (1) KR20170132152A (zh)
CN (1) CN107921005A (zh)
AU (1) AU2016219004A1 (zh)
CA (1) CA2976526A1 (zh)
HK (1) HK1252369A1 (zh)
PH (1) PH12017501420A1 (zh)
SG (1) SG11201706371VA (zh)
TW (1) TWI626061B (zh)
WO (1) WO2016131006A1 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019014718A2 (pt) * 2017-01-18 2020-03-10 Temasek Life Sciences Laboratory Limited Lipossomas hiperestabilizados aumentam o direcio-namento de células mitóticas
US10369230B2 (en) 2017-04-06 2019-08-06 National Guard Health Affairs Sustained release of a therapeutic agent from PLA-PEG-PLA nanoparticles for cancer therapy
CN109528686A (zh) * 2017-09-22 2019-03-29 杭州景杰生物科技有限公司 利用微混合和卡培他滨两亲性质的卡培他滨的聚合物-脂质混合纳米颗粒
CN111107842B (zh) * 2017-09-22 2021-10-08 杭州景杰生物科技股份有限公司 利用微混合和卡培他滨两亲性特性的卡培他滨的聚合物-脂质混杂纳米颗粒
PE20211468A1 (es) * 2018-11-02 2021-08-05 Tesorx Pharma Llc Quimioterapia intraperitoneal mejorada con liposomas
EP3701943A1 (en) * 2019-02-26 2020-09-02 CAPNOMED GmbH Delayed delivery of anticancer drugs
CN110478332A (zh) * 2019-09-12 2019-11-22 青岛科技大学 一种新型聚乙二醇-聚γ丁内酯两嵌段共聚物纳米载药微球的制备方法
CN110964816A (zh) * 2019-11-20 2020-04-07 深圳市鲲鹏未来科技有限公司 包含血液稳定性纳米颗粒的溶液、其制备方法及miRNA标志物的检测方法
CN112535678A (zh) * 2020-12-28 2021-03-23 烟台大学 连接曲妥珠单抗的美登素纳米粒组合物
CN112675313A (zh) * 2020-12-28 2021-04-20 烟台大学 连接曲妥珠单抗片段的美登素纳米粒组合物
KR102490940B1 (ko) 2021-01-08 2023-01-19 충북대학교 산학협력단 도세탁셀 및 오스톨이 봉입된 폴리에틸렌 글리콜-폴리카프로락톤 공중합체 마이셀 및 이의 용도
KR102576559B1 (ko) 2021-06-14 2023-09-08 충북대학교 산학협력단 도세탁셀 및 아파티닙이 봉입된 알부민 나노입자 및 이의 용도
KR102584649B1 (ko) 2021-07-13 2023-10-04 충북대학교 산학협력단 펜벤다졸 및 라파마이신이 봉입된 폴리에틸렌 글리콜-폴리카프로락톤 공중합체 마이셀 및 이의 용도
CN114432248B (zh) * 2022-01-28 2023-05-12 潍坊科技学院 一种靶向复合载体、载药体系、制备方法及其用途
KR20240050074A (ko) 2022-10-11 2024-04-18 충북대학교 산학협력단 젬시타빈 및 라파마이신이 봉입된 온도민감성 plga-peg-plga 하이드로겔 및 이의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485320B2 (en) * 2000-09-25 2009-02-03 Industrial Technology Research Institute Liposome for incorporating large amounts of hydrophobic substances
TWI262798B (en) * 2003-12-31 2006-10-01 Ind Tech Res Inst Liposome and drug deliver system
GR20060100144A (el) * 2006-03-03 2007-10-17 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene
CN100496609C (zh) * 2006-12-30 2009-06-10 上海艾力斯医药科技有限公司 一种稳定的脂质体组合物
US20110195030A1 (en) * 2008-10-15 2011-08-11 The University Of North Carolina At Chapel Hill Nanoparticle compositions comprising liquid oil cores
CN101869712B (zh) * 2009-04-21 2016-01-20 财团法人工业技术研究院 使用包囊抗肿瘤药物的聚合胶束用于治疗肿瘤的药物组合物
CN101889982B (zh) * 2010-04-15 2012-12-26 山东京卫制药有限公司 一种长循环脂质体组合物及其制备方法
EP2642979A4 (en) * 2010-11-26 2014-09-17 Univ Witwatersrand Jhb PHARMACEUTICAL COMPOSITION
WO2012116272A2 (en) * 2011-02-25 2012-08-30 South Dakota State University Polymer conjugated protein micelles
JP2014523444A (ja) * 2011-07-19 2014-09-11 エスティーシー． ユーエヌエム 癌の炎症性環境に基づいて治療用積載物を放出する、腹腔内投与されるナノ担体
EP3424564A1 (en) * 2011-10-31 2019-01-09 Mallinckrodt LLC Combinational liposome compositions for cancer therapy
CN103845290A (zh) * 2012-12-03 2014-06-11 曼丽国际有限公司 Umirolimus及其衍生物用于治疗癌症的用途
US20140271820A1 (en) * 2013-03-13 2014-09-18 Mallinckrodt Llc Liposome oxaliplatin compositions for cancer therapy
GB201312343D0 (en) * 2013-07-10 2013-08-21 Univ Aston Lipid-Containing Nanoparticle

Also Published As

Publication number Publication date
JP2018505224A (ja) 2018-02-22
CA2976526A1 (en) 2016-08-18
SG11201706371VA (en) 2017-09-28
US10016365B2 (en) 2018-07-10
EP3256110A4 (en) 2018-11-21
CN107921005A (zh) 2018-04-17
TW201632176A (zh) 2016-09-16
EP3256110A1 (en) 2017-12-20
KR20170132152A (ko) 2017-12-01
PH12017501420A1 (en) 2018-03-26
WO2016131006A1 (en) 2016-08-18
TWI626061B (zh) 2018-06-11
AU2016219004A1 (en) 2017-09-07
US20180028444A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
HK1252369A1 (zh) 利用納米顆粒治療腫瘤的組合物和方法
IL258955A (en) Preparations and methods for the treatment of cancer
IL273090B (en) Methods and preparations for the treatment of cancer
HK1247630A1 (zh) 用於增强癌症治療的效果的組合物和方法
HK1247931A1 (zh) 用於診斷和治療癌症的組合物和方法
IL268814A (en) Preparations and methods for the treatment of cancer
ZA201900960B (en) Methods and compositions for the treatment of cancer
IL254842B (en) Therapeutic preparations and methods for use in cancer treatment
EP3353204A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
IL249894A0 (en) Targeted medical nanoparticles and methods for their preparation and use
EP3328372A4 (en) COMPOSITIONS AND METHODS OF TREATING CANCER
ZA201808232B (en) Compositions and methods for the treatment of cancer
HK1258502A1 (zh) 用於治療高胱氨酸尿症的組合物和方法
EP3154952A4 (en) Methods and compositions for treatment of her-positive cancers
GB201511799D0 (en) Composition and methods of treatment
GB201621737D0 (en) Compositions and methods of treatment
DK3313207T3 (en) Compositions and methods for the treatment of malnutrition
GB201605127D0 (en) Composition and methods of treatment
GB201417248D0 (en) Compostion and methods of treatment
AU2015903210A0 (en) Compositions and methods of treatment
GB201512723D0 (en) Treatment of cancer
GB201418640D0 (en) Agents and methods for treatment of cancer
GB201507928D0 (en) Treatment of cancer
GB201504617D0 (en) Treatment of cancer
GB201410695D0 (en) Uses of oligouronates in cancer treatment